These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6423434)

  • 1. Binding of hypoglycaemic sulphonylureas to an artificial phospholipid bilayer.
    Deleers M; Malaisse WJ
    Diabetologia; 1984 Jan; 26(1):55-9. PubMed ID: 6423434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of tritiated S21403 to an artificial phospholipid bilayer.
    Malaisse WJ; Dard-Brunelle B
    Res Commun Mol Pathol Pharmacol; 1999 Mar; 103(3):269-74. PubMed ID: 10509738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.
    Hellman B; Sehlin J; Täljedal IB
    Acta Endocrinol (Copenh); 1984 Mar; 105(3):385-90. PubMed ID: 6230850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
    Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
    Biochim Biophys Acta; 1994 May; 1191(2):278-90. PubMed ID: 8172913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonylureas rapidly cross phospholipid bilayer membranes by a free-diffusion mechanism.
    Kamp F; Kizilbash N; Corkey BE; Berggren PO; Hamilton JA
    Diabetes; 2003 Oct; 52(10):2526-31. PubMed ID: 14514636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for more than one binding site for sulfonylureas in insulin-secreting cells.
    Verspohl EJ; Ammon HP; Mark M
    J Pharm Pharmacol; 1990 Apr; 42(4):230-5. PubMed ID: 1974288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells.
    Ozanne SE; Guest PC; Hutton JC; Hales CN
    Diabetologia; 1995 Mar; 38(3):277-82. PubMed ID: 7758873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.
    Meyer M; Chudziak F; Schwanstecher C; Schwanstecher M; Panten U
    Br J Pharmacol; 1999 Sep; 128(1):27-34. PubMed ID: 10498831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane insertion of cytochrome P450 1A2 promoted by anionic phospholipids.
    Ahn T; Guengerich FP; Yun CH
    Biochemistry; 1998 Sep; 37(37):12860-6. PubMed ID: 9737864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of transglutaminase by hypoglycaemic sulphonylureas in pancreatic islets and its possible relevance to insulin release.
    Gomis R; Mathias PC; Lebrun P; Malaisse-Lagae F; Sener A; Malaisse WJ
    Res Commun Chem Pathol Pharmacol; 1984 Dec; 46(3):331-49. PubMed ID: 6151221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes.
    Mayer P; Haas B; Celner J; Enzmann H; Pfeifer A
    Diabetes Obes Metab; 2011 Sep; 13(9):791-9. PubMed ID: 21477042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.
    Geisen K; Hitzel V; Okomonopoulos R; Pünter J; Weyer R; Summ HD
    Arzneimittelforschung; 1985; 35(4):707-12. PubMed ID: 3925960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca2+ in pancreatic B-cells.
    Garcia-Barrado MJ; Jonas JC; Gilon P; Henquin JC
    Eur J Pharmacol; 1996 Mar; 298(3):279-86. PubMed ID: 8846827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggregation of phospholipid vesicles by a chimeric protein with the N-terminus of annexin I and the core of annexin V.
    Andree HA; Willems GM; Hauptmann R; Maurer-Fogy I; Stuart MC; Hermens WT; Frederik PM; Reutelingsperger CP
    Biochemistry; 1993 May; 32(17):4634-40. PubMed ID: 8485141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of the hypoglycaemic sulphonylurea gliquidone. III. Conformational analysis.
    Lins L; Brasseur R; Malaisse WJ
    Pharmacol Res; 1996; 34(1-2):9-10. PubMed ID: 8981549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta.
    Löffler C; Quast U
    Br J Pharmacol; 1997 Feb; 120(3):476-80. PubMed ID: 9031752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sulphonylurea receptor may be an ATP-sensitive potassium channel.
    Sturgess NC; Ashford ML; Cook DL; Hales CN
    Lancet; 1985 Aug; 2(8453):474-5. PubMed ID: 2412077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles.
    Allen TM
    Biochim Biophys Acta; 1981 Jan; 640(2):385-97. PubMed ID: 7213898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects.
    Cerasi E; Efendic S; Thornqvist C; Luft R
    Acta Endocrinol (Copenh); 1979 Jun; 91(2):282-93. PubMed ID: 111449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes.
    Zhao L; Feng SS
    J Colloid Interface Sci; 2004 Jun; 274(1):55-68. PubMed ID: 15120278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.